Merck Bolsters Oncology Pipeline with $6.7B Acquisition of Terns Pharmaceuticals
Key Takeaways
- Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment.
- The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Mentioned
Key Intelligence
Key Facts
- 1Merck will acquire Terns Pharmaceuticals for $6.7 billion in an all-cash deal at $53 per share.
- 2The primary acquisition target is TERN-701, a Phase 2 allosteric BCR-ABL inhibitor for leukemia.
- 3The deal is a strategic response to the upcoming 2028 patent expiration of Merck's blockbuster drug Keytruda.
- 4TERN-701 will directly compete with Novartis' Scemblix in the chronic myeloid leukemia (CML) market.
- 5This acquisition follows Merck's recent multi-billion dollar purchases of Prometheus and Harpoon Therapeutics.
Who's Affected
Analysis
The pharmaceutical landscape shifted significantly this week as Merck & Co. announced its intention to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion. This acquisition represents a calculated maneuver by Merck to fortify its hematology-oncology pipeline, specifically targeting the chronic myeloid leukemia (CML) market. At the heart of the deal is TERN-701, a potent, allosteric BCR-ABL inhibitor currently in Phase 2 development. By bringing Terns into its fold, Merck is not only acquiring a high-potential clinical asset but also signaling its intent to challenge established players in the blood cancer space, most notably Novartis.
Industry analysts view this move through the lens of the looming 'Keytruda cliff.' Merck’s flagship immunotherapy, Keytruda, which has dominated the oncology market for years, is set to lose patent protection in 2028. With Keytruda accounting for a massive portion of Merck's annual revenue, the company has been under intense pressure to execute a 'string of pearls' M&A strategy—acquiring smaller, innovative biotech firms to build a diversified revenue stream for the next decade. The Terns acquisition follows a series of similar high-profile deals, including the $10.8 billion purchase of Prometheus Biosciences and the $680 million acquisition of Harpoon Therapeutics, all aimed at filling the eventual revenue gap left by Keytruda.
announced its intention to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion.
TERN-701 is particularly attractive because of its mechanism of action. As an allosteric inhibitor, it targets the ABL myristoyl pocket, a different site than traditional tyrosine kinase inhibitors (TKIs). This approach is designed to offer better selectivity and a improved safety profile, potentially overcoming resistance seen with older therapies. This puts Merck in direct competition with Novartis’ Scemblix, which currently holds a strong position in the allosteric CML treatment market. If TERN-701 continues to show positive data in clinical trials, Merck could leverage its massive global commercial infrastructure to rapidly gain market share upon approval.
What to Watch
For Terns Pharmaceuticals, the $53 per share cash offer represents a substantial premium over its recent trading price, rewarding shareholders for the company's focused development of its oncology and metabolic pipelines. While Terns had also been developing treatments for obesity and NASH, the Merck deal highlights the immense value currently placed on late-stage oncology assets that offer clear differentiation from existing standards of care. The acquisition is expected to close in the coming months, pending customary regulatory approvals and closing conditions.
Looking forward, the market will be watching for Merck’s integration strategy and how it prioritizes TERN-701 within its broader clinical program. There is also speculation that Merck may look to combine TERN-701 with other assets in its pipeline to create novel combination therapies for various hematological malignancies. This deal underscores a broader trend in the biopharma industry where large-cap companies are willing to pay significant premiums for de-risked, Phase 2 or Phase 3 assets that can provide a clear path to commercialization within a three-to-five-year window. As the 2028 deadline approaches, Merck is likely to remain one of the most active players in the M&A arena, continuing to scout for innovations that can sustain its leadership in the oncology sector.
Timeline
Timeline
Clinical Progress
Terns Pharmaceuticals advances TERN-701 through early-stage clinical trials for CML.
Acquisition Announcement
Merck announces definitive agreement to buy Terns for $6.7 billion.
Keytruda Patent Cliff
Merck faces the loss of exclusivity for its top-selling cancer immunotherapy.
Expected Closing
Anticipated completion of the acquisition following regulatory reviews.
Sources
Sources
Based on 2 source articles- STAT NewsSTAT+: Merck to buy Terns Pharmaceuticals in $6.7B dealMar 25, 2026
- BloombergMerck to Buy Terns for $6.7B to Grow in Blood CancersMar 25, 2026
From the Network
Merck Acquires Terns for $6.7B to Hedge Against Keytruda Patent Cliff
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on
BiotechMerck to Acquire Terns for $6.7B to Mitigate Keytruda Patent Cliff
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leuke
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |